COMP <GO>
KRYS vs IBRX // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Krystal Biotech Inc. (NASDAQ) VS. ImmunityBio Inc. (NASDAQ) • 15-METRIC TALLY: KRYS 7
— IBRX 4
■ METRIC PARITY
LAST: $332.29 (+2.38%) • MKT CAP: $9.61B
options-implied-move
—
LAST: $8.29 (-5.15%) • MKT CAP: $9.26B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KRYS VS. IBRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KRYS | IBRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.50% | -27.30% | +43.80 | KRYS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 53.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.97% | -3.33% | +5.30 | KRYS | /fcf-yield <GO> |
| Operating Margin | 41.50% | -60.00% | +101.50 | KRYS | /operating-margins <GO> |
| Net Profit Margin | 52.60% | -60.00% | +112.60 | KRYS | /net-margins <GO> |
| Revenue Growth (YoY) | 33.90% | 180.00% | -146.10 | IBRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 0.45 | +25.55 | KRYS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 6/9 | +2.00 | KRYS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.2 | 49.0 | -0.80 | IBRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 1.05 | -0.14 | IBRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.4x | 29.0x | +10.40 | IBRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.61B | $9.26B | $343.3M | KRYS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KRYS REV | IBRX REV | KRYS GROSS % | IBRX GROSS % | KRYS FCF | IBRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $389.1M | $113.3M | — | 99.3% | $188.9M | -$308.8M |
| FY 2024 | $290.5M | $14.7M | — | 100.0% | $119.2M | -$398.1M |
| FY 2023 | $50.7M | $622.0K | — | — | -$91.1M | -$366.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KRYS // BETA 0.91
IBRX // BETA 1.05